Evidence map›Paper›PMID 26856326›Full record

SynthesisHepatology international2016

Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.

Guiliang Wang, Yan Liu, Shu-Feng Zhou, Ping Qiu, Linfang Xu, Ping Wen, Jianbo Wen, Xianzhong Xiao

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Hepatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Treatment strategies for locally advanced hepatocellular carcinoma.Translational gastroenterology and hepatology · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Guiliang WangDepartment of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People's Republic of China.
Yan LiuDepartment of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People's Republic of China.
Shu-Feng ZhouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, 33612, USA.
Ping QiuDepartment of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People's Republic of China.
Linfang XuDepartment of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People's Republic of China.
Ping WenDepartment of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People's Republic of China.
Jianbo WenDepartment of Digestive Internal Medicine, Gan Nan Medical University Pingxiang Hospital, 128 Guangchang Road, Pingxiang, 337055, Jiangxi, People's Republic of China.
Xianzhong XiaoLaboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, Hunan, 410008, People's Republic of China. xianzhongxiaoxxz@sina.com.
307th Hospital of Chinese People’s Liberation Army · CNCentral South University · CNUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCombination therapy of sorafenib and transarterial chemoembolization (TACE) has shown benefits in treating advanced hepatocellular carcinoma (HCC). This study evaluated the efficacy and safety of TACE + sorafenib.

methodsMEDLINE, the Cochrane Library, EMBASE, and the ISI Web of Knowledge were searched (until 31 December 2013) for studies comparing TACE and TACE + sorafenib in treating patients with advanced HCC. Sensitivity and quality assessments were performed.

resultsFive comparative studies (2 were randomized control trials) that included 899 patients were used in the meta-analysis. Patients treated with TACE + sorafenib had better prognoses in terms of time to progression (TTP) compared to those with TACE + placebo or TACE alone; hazard ratios (HRs) ranged from 0.40 to 0.87, with the combined HR 0.61 (95 % CI 0.39-0.95, p = 0.031). However, the combined HR for overall survival (OS) did not differ significantly between patients treated with TACE + sorafenib and those with TACE + placebo or TACE alone (combined HR = 0.79, 95 % CI = 0.54-1.16, p = 0.235). Sensitivity analysis indicated the findings for TTP may be overly influenced by at least one of the studies.

conclusionsIn summary, our meta-analysis found that TACE + sorafenib can improve TTP. We did not find the combined therapy improved OS. Additional randomized controlled studies are necessary to further investigate the clinical benefit of TACE + sorafenib in treating advanced HCC.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyHumansLiver NeoplasmsNiacinamidePhenylurea CompoundsSorafenibAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenibCombined modality therapyLiver neoplasmsMeta-analysisSorafenibSystematic reviewTherapeutic chemoembolization

Identifiers

PMID26856326
OpenAlexW2271549170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.